PDCD1 and melanoma: As shown in Supplementary Table S1, there were no statistically significant differences in key prognostic variables — including age, sex, disease stage, Breslow thickness, ulceration status, lymph node involvement, melanoma subtype, mitotic index, BRAF mutation status, or anti–PD-1 agent — between patients with and without cutaneous irAEs.